✦ LIBER ✦

Pharmacodynamics and pharmacokinetics of YM128, a GPIIb/IIIa antagonist prodrug

✍ Scribed by Ken-ichi Suzuki; Yumiko Moritani; Nami Hisamichi; Masato Ichihara; Seijiro Akamatsu; Hiroshi Arai; Hiroshi Matsushima; Tomoko Nii; Kazuo Sato; Yuta Taniuchi; Takeshi Shigenaga; Seiji Kaku; Tomihisa Kawasaki; Yuzo Matsumoto; Osamu Inagaki; Kenichi Tomioka; Isao Yanagisawa

Book ID: 102143739
Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 287 KB
Volume: 55
Category: Article
ISSN: 0272-4391
DOI: 10.1002/ddr.10047

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prodrug and Analog Approaches to Improvi

Prodrug and Analog Approaches to Improving the Intestinal Absorption of a Cyclic Peptide, GPIIb/IIIa Receptor Antagonist

✍ Hiroshi Saitoh; Bruce J. Aungst 📂 Article 📅 1997 🏛 Springer US 🌐 English ⚖ 424 KB

Pharmacokinetics, Pharmacodynamics, and

Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist

✍ Lai, E; Wenning, LA; Crumley, TM; De Lepeleire, I; Liu, F; de Hoon, JN; Van Heck 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 348 KB

Pharmacokinetics and Pharmacodynamics of

Pharmacokinetics and Pharmacodynamics of Low-Molecular-Weight Heparins and Glycoprotein IIb/IIIa Receptor Antagonists in Renal Failure

✍ Brian S. Smith; Pritesh J. Gandhi 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 114 KB

Pharmacokinetic and pharmacodynamic effe

Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2vasopressin receptor antagonist in normal subjects

✍ M. Burnier; A. F. Fricker; D. Hayoz; J. Nussberger; H. R. Brunner 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 110 KB

Quantitative detection of platelet GPIIb

Quantitative detection of platelet GPIIb-IIIa receptor antagonist activity using a flow cytometric method

✍ Lisa J. Green; Philip Marder; Suzane L. Um; Joseph A. Jakubowski; Jeffry B. Lawr 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

Platelet-membrane surface receptors are important targets for pharmacologic intervention in cardiovascular disease. Among these, glycoprotein (GP) IIb-IIIa is dominant and integrally involved in platelet aggregation and thrombus formation. When activated, GPIIb-IIIa binds soluble fibrinogen (Fb) in

Tolerability, pharmacokinetics, and phar

Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist

✍ Paul L. M. van Giersbergen; Jasper Dingemanse 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 144 KB